FDA grants approval of Xolair (omalizumab) prefilled syringe formulation
Basel, 01 October 2018 FDA grants approval of Xolair (omalizumab) prefilled syringe formulation Xolair, the only biologic approved for both allergic asthma and chronic idiopathic urticaria indications, is now also approved in a prefilled syringe (PFS) formulation More than 330,000 patients have been treated with Xolair in the last 15 years The 75 mg/0.5 mL... Read more